ArticleHaematologica2024

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.

James Godfrey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.